FORIAN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.62 USD | -4.73% |
|
-4.03% | -10.43% |
| May. 14 | Forian Seeks Acquisitions | CI |
| May. 14 | Transcript : Forian Inc., Q1 2024 Earnings Call, May 14, 2024 |
Financials (USD)
| Sales 2024 * | 22.46M | Sales 2025 * | 27.2M | Capitalization | 81.53M |
|---|---|---|---|---|---|
| Net income 2024 * | -2M | Net income 2025 * | - | EV / Sales 2024 * | 3.63 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3 x |
| P/E ratio 2024 * |
-37.4
x | P/E ratio 2025 * |
-262
x | Employees | 37 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on Forian Inc.
More press releases
| 1 day | -4.73% | ||
| 1 week | -4.03% | ||
| Current month | +0.19% | ||
| 1 month | -3.68% | ||
| 3 months | -16.03% | ||
| 6 months | -7.75% | ||
| Current year | -10.43% |
1 week
2.60
2.82
1 month
2.592.85
Current year
2.314.15
1 year
1.854.15
3 years
1.8514.39
5 years
1.8545.00
10 years
1.8545.00
| Managers | Title | Age | Since |
|---|---|---|---|
Max Wygod
CEO | Chief Executive Officer | 36 | 20-10-14 |
Adam Dublin
FOU | Founder | 58 | 20-10-14 |
Michael Vesey
DFI | Director of Finance/CFO | 62 | 21-09-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stanley Trotman
BRD | Director/Board Member | 80 | 21-03-01 |
Mark Adler
BRD | Director/Board Member | 67 | 21-03-01 |
Ian Banwell
BRD | Director/Board Member | 60 | 21-03-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 2.62 | -4.73% | 9,149 |
| 24-05-24 | 2.75 | +3.00% | 5,568 |
| 24-05-23 | 2.67 | 0.00% | 4,131 |
| 24-05-22 | 2.67 | -2.20% | 39,729 |
| 24-05-21 | 2.73 | +2.29% | 7,419 |
Delayed Quote Nasdaq, May 28, 2024 at 04:30 pm EDT
More quotes
Forian Inc. is a technology solutions company. The Company provides a suite of data management capabilities and data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments. The Companyâs operations consist of providing analytic and information services to the healthcare and related industries, which are all subscription and services-based solutions. The Companyâs offerings include commercial, Real World Evidence (RWE) and market access solutions and data-driven insights to optimize the operational, clinical and financial performance of its customers. The Company provides its information solutions both as an enabling technology to consultants and service providers serving the healthcare and life sciences industries, as well as to end users in the healthcare and life sciences industries.
Sector
Software
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.62
USD
Average target price
5
USD
Spread / Average Target
+90.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.43% | 81.53M | |
| +14.43% | 3,198B | |
| +14.18% | 90.08B | |
| +8.75% | 80.61B | |
| -13.37% | 54.83B | |
| +22.60% | 46.88B | |
| +32.14% | 46.51B | |
| -30.71% | 42.9B | |
| +71.93% | 39.99B | |
| -2.58% | 26.87B |
- Stock Market
- Equities
- FORA Stock
